Sweden · Delayed Price · Currency is SEK Gabather AB Earnings Call Transcripts
Fiscal Year 2025
-
GT002, a novel pro-cognitive GABA modulator, is in phase 2 trials for schizophrenia, with key results expected by mid-2025. A provisional US patent was filed for its unique neural fingerprint, and partnership discussions with major pharma are ongoing, targeting a licensing deal next year.
-
GT002, a selective GABA A modulator, is advancing to phase II trials for cognitive impairment in schizophrenia, with strong safety data and unique biomarker-driven development. Licensing discussions are ongoing, and first patient data is expected by end of Q1 next year.
-
A fully funded Phase II trial for GT-002 in schizophrenia is set to start in Q1, with preliminary data expected in Q3. The company is targeting a licensing deal by Q4 2025, supported by a strong safety profile and broad market potential for its lead candidate.